Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/127550
Serious drug-induced liver disease secondary to ezetimibe
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins. Its use has been spreading over the last years. Ezetimibe was considered a safe drug. We report a case of a woman who developed a serious hepatocellular drug-induced liver disease after 4 mo therapy with 10 mg daily of ezetimibe. After withdrawal of the drug, the patient recovered slowly. Ezetimibe may produce serious toxic hepatitis and prompt withdrawal is mandatory in case of a significant abnormality in liver testing after beginning or during treatment with ezetimibe.
Matèries (anglès)
Citació
Citació
CASTELLOTE ALONSO, José, ARIZA CARDENAL, Javier, ROTA ROCA, Rosa, GIRBAU, Anna, XIOL QUINGLES, Xavier. Serious drug-induced liver disease secondary to ezetimibe. _World Journal of Gastroenterology_. 2008. Vol. 14, núm. 32, pàgs. 5098-5099. [consulta: 24 de desembre de 2025]. ISSN: 1007-9327. [Disponible a: https://hdl.handle.net/2445/127550]